Diammonium Glycyrrhizinate

Name: Diammonium Glycyrrhizinate
Brand: MedChemExpress
SKU: HY-N6804
Rating: 4.5 (1 reviews)

Cat. No.: HY-N6804 Purity: 99.94%: Data Sheet
SDS

COA
Handling Instructions
FAQs
Technical Support

Diammonium glycyrrhizinate is a substance that can be extracted and purified from a traditional Chinese medicinal herb. Diammonium glycyrrhizinate has anti-inflammatory effect, resistance to biologic oxidation, membranous protection and a weak steroidal action. Diammonium glycyrrhizinate exerts protective effect by downregulating inflammation cytokines, suppressing the NF-κB pathway, and restoring superoxide dismutase. Diammonium glycyrrhizinate can be used as a hepatic protector and can therefore be studied in research for most liver diseases.

For research use only. We do not sell to patients.

Diammonium Glycyrrhizinate Chemical Structure

CAS No. : 79165-06-3

Size	Stock	Quantity

Free Sample (0.1 - 0.5 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	Get quote
200 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All NF-κB Isoform Specific Products:

View All Isoforms

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Diammonium glycyrrhizinate (Compound DG) (0.001 mg/mL, 1 h before Aβ_1-42) decreases the mRNA levels of TNF-α, COX-2, iNOS, and IL-1β increased by Aβ_1-42 (5 μM)^[4].
Diammonium glycyrrhizinate (0.001 mg/mL, 6-24 h) markedly increases the cell viability of HT22 and SH-SY5Y cell lines^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Immunofluorescence^[4]

Cell Line:	BV-2 cells
Concentration:	0.001 mg/mL
Incubation Time:	1 h before Aβ_1-42 (5 μM for 6 h)
Result:	Attenuated Aβ_1-42-induced NF-κB nuclear translocation.

In Vivo

Diammonium glycyrrhizinate (Compound DG) (40 mg/kg, i.p., every day for 1 week) significantly improves the inflammatory indices in SD rats received acetic acid^[1].
Diammonium glycyrrhizinate (75-200 mg/kg, i.p., 2 h before the Concanavalin A (HY-P2149) injection) inhibits the increase of both ALT and AST levels in liver-injury mice model^[2].
Diammonium glycyrrhizinate (131.69-2250 mg/kg, i.p., single dose) results in LD₅₀ values of 525.10 mg/kg and 997.26 mg/kg for male and female ICR mice^[3].
Diammonium glycyrrhizinate (15-120 mg/kg, i.p., single dose) returns the difference of the serum sodium with the addition of Oxymatrine (HY-N0158) (15-60 mg/kg) in ICR mice^[3].
Diammonium glycyrrhizinate (90 mg/kg, i.p., single dose) results in significantly higher serum sodium levels in ICR mice^[3].
Diammonium glycyrrhizinate (10 mg/kg/day, i.p., 14 d) significantly decreases the mRNA levels of COX-2, TNF-α, iNOS, and IL-1β whilst increasing mRNA level of IL-10 in AD mice^[4].
Diammonium glycyrrhizinate (150 mg/kg/day, i.p., alternate days for 14 w) remarkedly decreases the epididymal adipose tissues in HFD-fed C57BL/6J mice^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SD rats received colonic infusion of acetic acid (30 mg/kg)^[1]
Dosage:	40 mg/kg
Administration:	Intraperitoneal injection (i.p.), every day for 1 week
Result:	Significantly improved the inflammatory indices including disease activity index, morphologic injury, histological changes and MPO activity. Significantly reduced the positive percentages and density of TNF-α, ICAM-1, and NF-κB p65, indicating the inhibition of their expression.

Animal Model:	Immune-mediated liver-injury mice model induced by Concanavalin A (20 mg/kg, i.v.)^[2]
Dosage:	75, 200 mg/kg
Administration:	Intraperitoneal injection (i.p.), 2 h before the Concanavalin A injection
Result:	Resulted in lower ALT levels and damage score. Resulted in a marked decrease in the expression level of cleaved-caspase 3. Downregulated the mRNA level of TNF-α and IL-6. Significantly decreased the apoptosis level of CD8⁺ T cells and showed a lower apoptosis phenomenon of CD4⁺ T cells. Inhibited the proliferation of the CD8⁺CD69⁺ subset in the splenocytes. Upregulated the percentage of CD4⁺CD25^-CD69⁺ subset in liver. Promoted CD4⁺CD25⁺Foxp3⁺ Tregs proliferation while inhibiting NKT cells proliferation.

Animal Model:	HFD-fed C57BL/6J mice (4 w, 18-22 g)^[5]
Dosage:	150 mg/kg/day
Administration:	Intraperitoneal injection (i.p.), alternate days for 14 w
Result:	Significantly ameliorates liver steatosis. Prominently decreased the serum level of TG. Prevented NAFLD development. Increased the number of OTUs. Notably increased the species richness of the gut microbiota in mice and had a modulation of effects on the gut microbiota structure. Restored the low SCFA production induced by NAFLD. Reduced the intestinal low-grade inflammation in the NAFLD mice. Increased the goblet cell number and mucin production.

Clinical Trial

Molecular Weight

856.99

Formula

C₄₂H₆₈N₂O₁₆

CAS No.

79165-06-3

Appearance

Solid

Color

White to off-white

SMILES

C[C@]12[C@@](C(C=C3[C@]2(CC[C@@]4([C@@]3([H])C[C@](C)(CC4)C(O)=O)C)C)=O)([H])[C@@]5([C@@](C(C)([C@H](CC5)O[C@@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(O)=O)O)O)O[C@@H]7O[C@@H]([C@H]([C@@H]([C@H]7O)O)O)C(O)=O)C)([H])CC1)C.N.N

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (116.69 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : ≥ 100 mg/mL (116.69 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.1669 mL	5.8344 mL	11.6687 mL
5 mM	0.2334 mL	1.1669 mL	2.3337 mL
10 mM	0.1167 mL	0.5834 mL	1.1669 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.92 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.92 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (2.92 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.94%

Select Batch:

Data Sheet (286 KB) SDS (393 KB)

COA (258 KB) HNMR (304 KB) LCMS (100 KB)

Handling Instructions (2659 KB)

References

[1]. Yuan H, et al. Anti-inflammatory effect of Diammonium Glycyrrhizinate in a rat model of ulcerative colitis. World J Gastroenterol. 2006 Jul 28;12(28):4578-81. [Content Brief]

[2]. Gao, M., et al., (2019). Diammonium Glycyrrhizinate Mitigates Liver Injury Via Inhibiting Proliferation Of NKT Cells And Promoting Proliferation Of Tregs. Drug design, development and therapy, 13, 3579–3589. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO / H₂O	1 mM	1.1669 mL	5.8344 mL	11.6687 mL	29.1719 mL
	5 mM	0.2334 mL	1.1669 mL	2.3337 mL	5.8344 mL
	10 mM	0.1167 mL	0.5834 mL	1.1669 mL	2.9172 mL
	15 mM	0.0778 mL	0.3890 mL	0.7779 mL	1.9448 mL
	20 mM	0.0583 mL	0.2917 mL	0.5834 mL	1.4586 mL
	25 mM	0.0467 mL	0.2334 mL	0.4667 mL	1.1669 mL
	30 mM	0.0389 mL	0.1945 mL	0.3890 mL	0.9724 mL
	40 mM	0.0292 mL	0.1459 mL	0.2917 mL	0.7293 mL
	50 mM	0.0233 mL	0.1167 mL	0.2334 mL	0.5834 mL
	60 mM	0.0194 mL	0.0972 mL	0.1945 mL	0.4862 mL
	80 mM	0.0146 mL	0.0729 mL	0.1459 mL	0.3646 mL
	100 mM	0.0117 mL	0.0583 mL	0.1167 mL	0.2917 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.